Continuous subcutaneous insulin infusion (CSII, or insulin pump) and continuous glucose monitoring (CGM) sensors have been increasingly used and associated with improved glycemic control by people with type 1 diabetes and insulin-requiring type 2 diabetes. Commonly used infusion sets in most CSII systems are limited to a wear time of 3 days. In contradistinction, CGM sensors are currently approved for seven and more days of wear. With the motivation to provide a 7-day infusion set that matches the CGM wear time and to improve patient experience, the recently CE-marked and FDA 510k–cleared Medtronic extended infusion set (EIS) was designed.s The EIS offers enhanced new features that include use for up to 7 days, improved convenience, comfort, and better quality of life for insulin pump users.
CITATION STYLE
Zhang, G., Cohen, O., & Chattaraj, S. (2024). Development of the Extended Infusion Set and Its Mechanism of Action. Journal of Diabetes Science and Technology, 18(2), 454–459. https://doi.org/10.1177/19322968221112120
Mendeley helps you to discover research relevant for your work.